The Google Ventures-backed genome editing technology company has raised $163m in equity across two rounds.
Editas Medicine, a US-based genome editing company backed by corporate venturing unit Google Ventures, filed for a $100m initial public offering on Nasdaq on Monday.
Founded in 2013, Editas is developing a genome editing platform that will form the basis of therapies for diseases caused by genetic defects. It is also researching treatments for infectious and oncologic diseases that affect the liver, lung, blood, eye and muscle.
Between $15m and $20m of the proceeds from the offering will fund…
